OncoMatch/Clinical Trials/NCT05100862
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Is NCT05100862 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Zanubrutinib and Rituximab for relapsed/refractory follicular lymphoma.
Treatment: Zanubrutinib · Rituximab · Lenalidomide · Obinutuzumab — The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Prior therapy
Must have received: anti-CD20 agent
Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy
Cannot have received: lenalidomide or drug from same class (lenalidomide)
Exception: if without response (partial or complete) or short remission duration (< 24 months)
Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (< 24 months)
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ucsf Fresno University of California San Francisco Fresno · Fresno, California
- Kaiser Permanente Southern California · Irvine, California
- Cancer and Blood Specialty Clinic · Los Alamitos, California
- Los Angeles Cancer Network · Los Angeles, California
- Valkyrie Clinical Trials · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify